- Joined
- Aug 3, 2007
- Messages
- 935
- Reaction score
- 617
Was looking at some figures in our practice recently and now starting to see the effects from the fee scheduling changes enacted at the beginning of the year. With the new CMS coding of an 88344 issued for prostate cocktails, reimbursement has been drastically altered. Just talked with my lab manager today and he said the 88344 Part B Medicare reimbursement for a PIN-4 is roughly $240 whether we do it for 1 or 12 parts. The cost of reagents is $63 per specimen. That means if you’re running it on all specimens in a twelve-part biopsy (like some practices have been known to do) that’s going to cost $756. For those who run it on all twelve parts, they will be losing about $500 per case for their hospital/lab on Medicare patients. Heck, even if there were multiple areas with ASAP, only four can be stained just to breakeven on the technical. Sure, the pathologists are coming out ahead on the professional component, but you could see how this will be curtailed when hospitals are crunching numbers and start seeing the loss. Once again, we’re seeing how the questionably greedy practices of a few have caused the pendulum to swing too far the other way and affect the masses… Did anyone else’s practice get hit; and if so, how significantly? Are there any coding modifiers or anything else you guys are doing or just chalk it up as a loss?
Last edited: